Remove 2026 Remove Competition Remove Leads
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. The MFPs will be announced publicly in September 2024 and go into effect on January 1, 2026. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

article thumbnail

Internet of Things related social media posts decreased by 9% in the pharma industry in Q1 2023

Pharmaceutical Technology

GlobalData’s Internet of Things (IoT) Market report helps keep abreast of the latest trends in internet of things, market opportunity forecast and the competitive landscape. Of the 50 leading companies in the pharma industry, U.S. Buy the report here.

Media 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023

Pharmaceutical Technology

It provides forward-looking analysis of the market including market sizing up to 2026, segmentation by application, potential growth opportunities, and competitive pr Buy the report here.

article thumbnail

What a string of semaglutide biosimilars could mean for Mainland China

Clarivate

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).

article thumbnail

Connected customer data: a golden opportunity for pharma marketers

pharmaphorum

Research by Treasure Data , a market leading enterprise customer data platform (CDP), shows that HCPs are increasingly turning to digital to research scientific information, new medications, and brands. billion by 2026, according to research by the Business Research Company. Capturing market share. billion in 2021 to $9.23

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. Expect the nine competitors to explore Kotler’s 4Ps of Marketing to gain share in this lucrative and competitive marketplace.